COMPASS-HF Shows Monitor Reduces Heart Failure Hospital Events

Medtronic has announced results of the COMPASS-HF (Chronicle Offers Management to Patients with Advanced Signs and Symptoms of Heart Failure) clinical trial that were presented at the American College of Cardiology Annual Scientific Session.

COMPASS-HF evaluated the use of a new, investigational device, the Chronicle implantable hemodynamic monitor (IHM) that is designed to continuously track intracardiac pressure, body temperature, physical activity and heart rate in patients with systolic and diastolic heart failure (NYHA Class III and IV).

COMPASS-HF, supported by Medtronic, is the first randomized, controlled clinical trial to evaluate the utility of a continuous, ambulatory intracardiac pressure monitor to reduce heart failure hospitalizations and improve heart failure status. There was a 41-percent reduction in combined heart failure-related hospitalizations, ED and urgency care visits among NYHA Class III patients whose physicians had regular access to data transmitted from the Chronicle monitor (statistically significant).